IntraOp Medical
Corporation, a leading provider of innovative technology-based cancer
treatments, today announced the completion of its sale to an
investment group led by Firsthand Technology Value Fund. Inc.
SVVC, a publicly traded venture capital fund.
Throughout its restructuring process, IntraOp Medical continued to
manufacture and ship Mobetrons, as well as service existing
customers. In September, IntraOp shipped its eighth Mobetron to
China, to China Medical University in Shenyang City.
IntraOp's Mobetron is the only mobile, self-shielded electron linear
accelerator in the world. The Mobetron is used for intra-operative
electron radiation therapy (IOERT) to radiate cancerous tumors and
cells during surgery. U.S. News and World Report's top 10 hospitals
feature six Mobetrons, and there are more than 50 Mobetrons
worldwide.
More than 30 years of clinical trial data shows that IOERT reduces
the chance of the cancer returning and often also leads to longer
survival. IOERT bypasses healthy tissue and organs, providing
effective radiation directly to the cancer site, with less overall
radiation to the patient. "Everyone can appreciate the benefits and
logic behind delivering a cancer-killing dose of radiation directly
to the tumor bed, which in turn reduces or eliminates post-surgery
radiation and overall treatment time," said IntraOp CEO John Powers.
The Mobetron provides clinically proven, improved outcomes at lower
cost, saving money for hospitals, insurers, and patients. With a
clean balance sheet and a strong financial partner, IntraOp Medical
is confident that this restructuring positions the company to address
the growing demand for evidence-based medical treatments and
positively impact the lives of cancer patients.
About IntraOp
IntraOp Medical Corporation provides innovative technology solutions
for the treatment and eradication of cancer. Founded in 1993, IntraOp
is committed to providing the tools doctors need to administer IOERT
safely and effectively for all cancer patients. The Mobetron is the
first IOERT device designed for use in existing operating rooms and
has been used to treat over 20 different cancer indications. Mobetron
benefits include: increased survival rates, better local tumor
control, shorter treatment cycles, and happier patients with fewer
side effects. Leading hospitals and clinics throughout the world use
the Mobetron as a vital part of their comprehensive cancer program.
For more information email info@intraopmedical.com or call
408-636-1020 x128.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in